Skip to main content
Erschienen in: Der Gastroenterologe 6/2010

01.11.2010 | Schwerpunkt

Nuklearmedizinische Diagnostik in der Gastroenterologie

verfasst von: Prof. Dr. A.R. Stahl, S.J. Rosenbaum-Krumme, D. Steiner, L.S. Freudenberg

Erschienen in: Die Gastroenterologie | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch den Einzug der Positronenemissionstomographie (PET) in den 1990er Jahren hat die Darstellung metabolischer/molekularer Prozesse bei gastrointestinalen Tumoren erheblich an Bedeutung gewonnen. Zudem ist die Kombination mit morphologischen Schnittbildverfahren auf dem Vormarsch; dies gilt sowohl für die PET in Form von PET/CT, PET/MR als auch für konventionelle nuklearmedizinische Techniken (z. B. SPECT/CT).
Literatur
1.
Zurück zum Zitat Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18: 3202–3210PubMed Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18: 3202–3210PubMed
2.
Zurück zum Zitat Stahl A, Stollfuss J, Ott K et al (2005) FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin 44: 249–255; quiz N255–246PubMed Stahl A, Stollfuss J, Ott K et al (2005) FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin 44: 249–255; quiz N255–246PubMed
3.
Zurück zum Zitat Heeren PA, Jager PL, Bongaerts F et al (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45: 980–987PubMed Heeren PA, Jager PL, Bongaerts F et al (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45: 980–987PubMed
4.
Zurück zum Zitat Flamen P, Lerut A, Van Cutsem E et al (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085–1092CrossRefPubMed Flamen P, Lerut A, Van Cutsem E et al (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085–1092CrossRefPubMed
5.
Zurück zum Zitat Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30: 288–295CrossRefPubMed Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30: 288–295CrossRefPubMed
6.
Zurück zum Zitat Stahl A, Ott K, Schwaiger M, Weber WA (2004) Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31: 1471–1478CrossRefPubMed Stahl A, Ott K, Schwaiger M, Weber WA (2004) Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31: 1471–1478CrossRefPubMed
7.
Zurück zum Zitat De Potter T, Flamen P, Van Cutsem E et al (2002) Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29: 525–529CrossRef De Potter T, Flamen P, Van Cutsem E et al (2002) Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29: 525–529CrossRef
8.
Zurück zum Zitat Rosa F, Meimarakis G, Stahl A et al (2004) Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuklearmedizin 43: 135–140PubMed Rosa F, Meimarakis G, Stahl A et al (2004) Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuklearmedizin 43: 135–140PubMed
9.
Zurück zum Zitat Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 37: 862–869CrossRefPubMed Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 37: 862–869CrossRefPubMed
10.
Zurück zum Zitat Bipat S, Leeuwen MS van, Comans EF et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis – meta-analysis. Radiology 237: 123–131CrossRefPubMed Bipat S, Leeuwen MS van, Comans EF et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis – meta-analysis. Radiology 237: 123–131CrossRefPubMed
11.
Zurück zum Zitat Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22: 4357–4368CrossRefPubMed Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22: 4357–4368CrossRefPubMed
12.
Zurück zum Zitat Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290: 3199–3206CrossRefPubMed Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290: 3199–3206CrossRefPubMed
13.
Zurück zum Zitat Bohm B, Voth M, Geoghegan J et al (2004) Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130: 266–272CrossRefPubMed Bohm B, Voth M, Geoghegan J et al (2004) Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130: 266–272CrossRefPubMed
14.
Zurück zum Zitat Sendler A, Avril N, Helmberger H et al (2000) Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 24: 1121–1129CrossRefPubMed Sendler A, Avril N, Helmberger H et al (2000) Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 24: 1121–1129CrossRefPubMed
15.
Zurück zum Zitat Meisetschlager G, Poethko T, Stahl A et al (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47: 566–573PubMed Meisetschlager G, Poethko T, Stahl A et al (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47: 566–573PubMed
16.
Zurück zum Zitat Schirrmeister H, Glatting G, Hetzel J et al (2001) Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42: 1800–1804PubMed Schirrmeister H, Glatting G, Hetzel J et al (2001) Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42: 1800–1804PubMed
17.
Zurück zum Zitat Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: 900–908CrossRefPubMed Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: 900–908CrossRefPubMed
18.
Zurück zum Zitat Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21: 4604–4610CrossRefPubMed Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21: 4604–4610CrossRefPubMed
19.
Zurück zum Zitat Ott K, Weber WA, Fink U et al (2003) Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 27: 1035–1039CrossRefPubMed Ott K, Weber WA, Fink U et al (2003) Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 27: 1035–1039CrossRefPubMed
20.
Zurück zum Zitat Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45: 357–365PubMed Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45: 357–365PubMed
21.
Zurück zum Zitat Wong CY, Salem R, Raman S et al (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29: 815–820CrossRefPubMed Wong CY, Salem R, Raman S et al (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29: 815–820CrossRefPubMed
22.
Zurück zum Zitat Neurath MF, Vehling D, Schunk K et al (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97: 1978–1985CrossRefPubMed Neurath MF, Vehling D, Schunk K et al (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97: 1978–1985CrossRefPubMed
23.
Zurück zum Zitat Bunker SR, Lull RJ, Tanasescu DE et al (1984) Scintigraphy of gastrointestinal hemorrhage: superiority of 99mTc red blood cells over 99mTc sulfur colloid. Am J Roentgenol 143: 543–548 Bunker SR, Lull RJ, Tanasescu DE et al (1984) Scintigraphy of gastrointestinal hemorrhage: superiority of 99mTc red blood cells over 99mTc sulfur colloid. Am J Roentgenol 143: 543–548
24.
Zurück zum Zitat Sos TA, Lee JG, Wixson D, Sniderman KW (1978) Intermittent bleeding from minute to minute in acute massive gastrointestinal hemorrhage: arteriographic demonstration. Am J Roentgenol 131: 1015–1017 Sos TA, Lee JG, Wixson D, Sniderman KW (1978) Intermittent bleeding from minute to minute in acute massive gastrointestinal hemorrhage: arteriographic demonstration. Am J Roentgenol 131: 1015–1017
25.
Zurück zum Zitat Thorne DA, Datz FL, Remley K, Christian PE (1987) Bleeding rates necessary for detecting acute gastrointestinal bleeding with technetium-99m-labeled red blood cells in an experimental model. J Nucl Med 28: 514–520PubMed Thorne DA, Datz FL, Remley K, Christian PE (1987) Bleeding rates necessary for detecting acute gastrointestinal bleeding with technetium-99m-labeled red blood cells in an experimental model. J Nucl Med 28: 514–520PubMed
26.
Zurück zum Zitat Sfakianakis GN, Haase GM (1982) Abdominal scintigraphy for ectopic gastric mucosa: a retrospective analysis of 143 studies. Am J Roentgenol 138: 7–12 Sfakianakis GN, Haase GM (1982) Abdominal scintigraphy for ectopic gastric mucosa: a retrospective analysis of 143 studies. Am J Roentgenol 138: 7–12
27.
Zurück zum Zitat Wieder HA, BeerAJ, Lordick F (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46: 2029–2034PubMed Wieder HA, BeerAJ, Lordick F (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46: 2029–2034PubMed
Metadaten
Titel
Nuklearmedizinische Diagnostik in der Gastroenterologie
verfasst von
Prof. Dr. A.R. Stahl
S.J. Rosenbaum-Krumme
D. Steiner
L.S. Freudenberg
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Die Gastroenterologie / Ausgabe 6/2010
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-010-0432-x

Weitere Artikel der Ausgabe 6/2010

Der Gastroenterologe 6/2010 Zur Ausgabe

Neue Techniken

3D-Cholangiographie

CME Weiterbildung · Zertifizierte Fortbildung

Infektiöse Diarrhö

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.